Loading clinical trials...

COMPLETEDNA

Excimer Light in Psoriasis

Excimer Light Effect on Neurogenic Inflammation in Developing Versus Stationary Psoriasis Lesions

NCT05283876•Cairo University

Summary

The aim of this study is to determine the standard tissue levels of SP and its receptor in lesional skin of psoriasis patients in both developing and stationary stages before and after excimer light therapy.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Type of Psoriasis: plaque psoriasis.
•Less than 10% surface area.

Exclusion Criteria

•Erythrodermic psoriasis
•Pustular psoriasis
•Topical treatment for psoriasis for the past 2 weeks.
•Systemic retinoids in the last 2 years.
•Systemic treatments (including any drugs that affect SP level as Aprepitant) in the last 3 months.
•Contraindications to excimer light therapy (history of skin malignancy or precancerous conditions like xeroderma pigmentosum or photosensitivity)

Locations (1)

Kasr Al Ainy Faculty of medicine

Cairo, Egypt

Key Dates

Start Date

March 10, 2022

Primary Completion Date

March 30, 2023

Completion Date

March 30, 2023

Last Updated

February 8, 2024

Enrollment

ACTUAL participants

Conditions

Psoriasis

Interventions

Excimer light

DEVICE

A Study of Guselkumab After Switching From Ustekinumab in Participants With Moderate to Severe Psoriasis

NCT07449234

Psoriasis

View study

RECRUITINGPHASE3

Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)

NCT07116967

Plaque Psoriasis

View study

RECRUITINGPHASE3

A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis

NCT07250802

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 8, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Excimer Light in Psoriasis

Inclusion Criteria

Exclusion Criteria

A Study of Guselkumab After Switching From Ustekinumab in Participants With Moderate to Severe Psoriasis

Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)

A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis

An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis

Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis

Real-Life Evaluation of Guselkumab Dosing Interval Adjustments